- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03668990
Feasability, Validty and Reliability of Inertial Sensors
Feasibility, Validity and Reliability Kinematic Movement Analysis of Upper Limb Movements in Stroke and MS Patients Using Inertial Sensors
This study has 3 aimes:
- To investigate the feasibility of using IMUs (Xsens, MVN Studio) during functional tasks to assess upper limb kinematics in pwMS and stroke survivors. On the one hand, the feasibility of performing the tasks will be investigated . On the other hand, does the XSens give valuable data?
- To investigate the discriminative validity of kinematic measurements of upper limb movements post-stroke and pwMS in comparison with gender and age-matched healthy controls
- To investigate the test-retest reliability of the kinematic parameters collected during the different functional tasks in pwMS and stroke survivors
It is a cross-sectional case-controlled observational study, with 3 different groups: 25 Persons with Multiple sclerosis, 25 stroke patients and 50 healthy controls, matched by age and gender.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hasselt, Belgium, B-3500
- Jessa Ziekenhuis
-
Overpelt, Belgium, 3900
- Revalidatie & MS Centrum Overpelt
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion criteria for all participants: Healthy controls, pwsMS and stroke patients
- No orthopedic or neuro-muscular impairments in the upper limb
- Age > 18 years
- Able to understand and execute the test instructions
- Perceived pain in one of the upper limbs of more than 4/10 (Visual Analog Scale)
- Able to move a joint (wrist, elbow or shoulder) in the upper limb against gravity without resistance (Medical Research Council) (16).
Inclusion criteria for PwMS:
- Diagnosed with MS using McDonald criteria (17)
Inclusion criteria Stroke patients
- First- ever single, unilateral (ischemic or hemorrhagic)
- At least one month after stroke
- No apraxia or hemi spatial neglect
Exclusion Criteria:
Exclusion Criteria for pwMS only:
- a relapse 3 months before the start of the study
- A change of symptomatic medication during the testing period
Exclusion Criteria:
- People with predominantly ataxia or tremor are excluded from the reliability part of this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: persons with Multiple Sclerosis (MS)
25 persons with MS Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements. Funcitonal-oriented upper limb movements are performed at two different test days. |
It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
|
|
Other: stroke patients
25 stroke patients Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements. Funcitonal-oriented upper limb movements are performed at two different test days. |
It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
|
|
Other: Healthy controls
50 healthy controls Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements. Funcitonal-oriented upper limb movements are performed at two different test days. |
It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
kinematic parameter
Time Frame: day 2
|
The data received of the IMU's are the angles of point task achievement (PTA).
PTA is defined as the instant when the ROM, needed for successful task execution, was achieved.
Different joint angles of PTA will be calculated by MVN BIOMECH software.
Matlab (software version R2016b) and excel will be used to process the data.
|
day 2
|
|
kinematic parameter
Time Frame: day 3
|
The data received of the IMU's are the angles of point task achievement (PTA).
PTA is defined as the instant when the ROM, needed for successful task execution, was achieved.
Different joint angles of PTA will be calculated by MVN BIOMECH software.
Matlab (software version R2016b) and excel will be used to process the data.
|
day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Brunnström Fugl Meyer (BFM)
Time Frame: day 1
|
The Brunnström Fugl Meyer (BFM) was used to measure motor control at the body functions and structures level.
The upper limb section is applied: shoulder, elbow, forearm, wrist movements and grip
|
day 1
|
|
Action Research arm test
Time Frame: Day 1
|
which assessed the patient's ability to handle objects varying in size
|
Day 1
|
|
Trunk Impairment Scale
Time Frame: day 1
|
To examine the clinimetric characteristics of the Trunk Impairment Scale (TIS).
This scale evaluates motor impairment of the trunk after stroke.
The TIS scores, on a range from 0 to 23, static and dynamic sitting balance as well as trunk co-ordination.
It also aims to score the quality of trunk movement and to be a guide for treatment.
|
day 1
|
|
Manual Ability Measure-36 (questionnaire)
Time Frame: day1
|
Perceived performance on activity level
|
day1
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Joke Raats, drs, Hasselt University
- Study Chair: Liesbet De Baets, dr., Hasselt University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Kinematic01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; University of Copenhagen and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
Clinical Trials on IMUs (Xsens, MVN Studio)
-
Istituto Ortopedico RizzoliCompleted